Review
Version 1
Preserved in Portico This version is not peer-reviewed
Dendritic Cells Immunotherapy of Ovarian Cancer: Overview of Our Achievements
Version 1
: Received: 19 February 2024 / Approved: 20 February 2024 / Online: 20 February 2024 (07:05:17 CET)
A peer-reviewed article of this Preprint also exists.
Bartůňková, J. Dendritic Cell Immunotherapy for Ovarian Cancer: An Overview of Our Achievements. Onco 2024, 4, 46-55. Bartůňková, J. Dendritic Cell Immunotherapy for Ovarian Cancer: An Overview of Our Achievements. Onco 2024, 4, 46-55.
Abstract
Abstract
Epithelial ovarian carcinoma (EOC) is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. EOC is poorly responsive to immune check-point inhibitors due to immunologic features including limited tumor mutational burden (TMB), poor infiltration by immune cells and active immunosuppression. Thus, novel strategies are needed to overcome the frequent lack of preexisting immunity in patients with EOC. We developed and tested an autologous dendritic cell (DC)-based vaccine (DCVAC) which has recently been shown to be safe and to significantly improve progression-free survival (PFS) in two independent randomized phase II clinical trials enrolling patients with EOC (SOV01, NCT02107937; SOV02, NCT02107950). In addition, our exploratory data analyses suggest that the clinical benefits of DCVAC were more pronounced in patients with EOC with lower than-median TMB and scant CD8+ T cells infiltration. Thus, DC-based vaccine stands out as a promising clinical tool to jumpstart anticancer immunity in patients with immunologically „cold“ EOC. Our findings underscore the need for personalized immunotherapy and clinical relevance of potential tumor-related biomarkers within immunotherapy field. Additional clinical trials are needed to address these strategies as well as the potential value of TMB and immune infiltrate at baseline as biomarkers to guide the clinical management of EOC.
Keywords
ovarian cancer; dendritic cells; immunotherapy; tumor microenvironment
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
